Neutrophil to lymphocyte ratio and tumour burden for treatment efficacy stratification in renal cell carcinoma patients receiving nivolumab plus ipilimumab

Background: There is a lack of surrogate markers to predict the outcomes of nivolumab plus ipilimumab (Nivo-Ipi) for advanced renal cell carcinoma (RCC), but neutrophil to lymphocyte ratio (NLR) and tumour burden are promising candidates. This study investigated biological and radiological surrogate...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	M. Oshima, S. Washino, S. Shirotake, H. Takeshita, M. Inoue, Y. Miura, A. Nakayama, S. Nagamoto, T. Nakayama, K. Izumi, M. Oyama, S. Kawakami, K. Saito, Y. Matsuoka, T. Miyagawa
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2025-03-01
Schriftenreihe:	ESMO Real World Data and Digital Oncology
Schlagworte:	neutrophil to lymphocyte ratio tumour burden renal cell carcinoma nivolumab ipilimumab
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2949820124000845
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!